Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
3D-printed simulator for nasopharyngeal swab collection for COVID-19.
Koch A, Vermel M, Hansmann Y, Lodi M, Mura C, Sananes A, Gallien S, Wurtz É, Bleibtreu A, Martinot M, Exinger J, Lescure X, Kerneis S, Lacombe K, Mootien JY, Shawali C, Lecointre L, Debry C, Lefebvre N, Sananes N. Koch A, et al. Among authors: mootien jy. Infect Dis Now. 2022 May;52(3):138-144. doi: 10.1016/j.idnow.2022.02.002. Epub 2022 Feb 8. Infect Dis Now. 2022. PMID: 35149235 Free PMC article.
The BAS2IC Score: A Useful Tool to Identify Patients at High Risk of Early Progression to Severe Coronavirus Disease 2019.
Kaeuffer C, Ruch Y, Fabacher T, Hinschberger O, Mootien J, Eyriey M, Greigert V; COVID-19 Alsace Study Group; Meyer N, Fafi-Kremer S, Lefebvre N, Hansmann Y, Martinot M, Danion F. Kaeuffer C, et al. Open Forum Infect Dis. 2020 Sep 1;7(10):ofaa405. doi: 10.1093/ofid/ofaa405. eCollection 2020 Oct. Open Forum Infect Dis. 2020. PMID: 33274248 Free PMC article.
An open-label randomized controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19.
Ader F, Peiffer-Smadja N, Poissy J, Bouscambert-Duchamp M, Belhadi D, Diallo A, Delmas C, Saillard J, Dechanet A, Mercier N, Dupont A, Alfaiate T, Lescure FX, Raffi F, Goehringer F, Kimmoun A, Jaureguiberry S, Reignier J, Nseir S, Danion F, Clere-Jehl R, Bouiller K, Navellou JC, Tolsma V, Cabié A, Dubost C, Courjon J, Leroy S, Mootien J, Gaci R, Mourvillier B, Faure E, Pourcher V, Gallien S, Launay O, Lacombe K, Lanoix JP, Makinson A, Martin-Blondel G, Bouadma L, Botelho-Nevers E, Gagneux-Brunon A, Epaulard O, Piroth L, Wallet F, Richard JC, Reuter J, Staub T, Lina B, Noret M, Andrejak C, Lê MP, Peytavin G, Hites M, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy study group. Ader F, et al. Clin Microbiol Infect. 2021 Dec;27(12):1826-1837. doi: 10.1016/j.cmi.2021.05.020. Epub 2021 May 26. Clin Microbiol Infect. 2021. PMID: 34048876 Free PMC article. Clinical Trial.
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial.
Ader F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, Poissy J, Belhadi D, Diallo A, Lê MP, Peytavin G, Staub T, Greil R, Guedj J, Paiva JA, Costagliola D, Yazdanpanah Y, Burdet C, Mentré F; DisCoVeRy Study Group. Ader F, et al. Lancet Infect Dis. 2022 Feb;22(2):209-221. doi: 10.1016/S1473-3099(21)00485-0. Epub 2021 Sep 14. Lancet Infect Dis. 2022. PMID: 34534511 Free PMC article. Clinical Trial.
Clinical characteristics and risk factors associated with severe COVID-19: prospective analysis of 1,045 hospitalised cases in North-Eastern France, March 2020.
Kaeuffer C, Le Hyaric C, Fabacher T, Mootien J, Dervieux B, Ruch Y, Hugerot A, Zhu YJ, Pointurier V, Clere-Jehl R, Greigert V, Kassegne L, Lefebvre N, Gallais F; Covid Alsace Study Group; Meyer N, Hansmann Y, Hinschberger O, Danion F; COVID Alsace Study Group. Kaeuffer C, et al. Euro Surveill. 2020 Dec;25(48):2000895. doi: 10.2807/1560-7917.ES.2020.25.48.2000895. Euro Surveill. 2020. PMID: 33272355 Free PMC article.
Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial.
Trøseid M, Arribas JR, Assoumou L, Holten AR, Poissy J, Terzić V, Mazzaferri F, Baño JR, Eustace J, Hites M, Joannidis M, Paiva JA, Reuter J, Püntmann I, Patrick-Brown TDJH, Westerheim E, Nezvalova-Henriksen K, Beniguel L, Dahl TB, Bouscambert M, Halanova M, Péterfi Z, Tsiodras S, Rezek M, Briel M, Ünal S, Schlegel M, Ader F, Lacombe K, Amdal CD, Rodrigues S, Tonby K, Gaudet A, Heggelund L, Mootien J, Johannessen A, Møller JH, Pollan BD, Tveita AA, Kildal AB, Richard JC, Dalgard O, Simensen VC, Baldé A, de Gastines L, Del Álamo M, Aydin B, Lund-Johansen F, Trabaud MA, Diallo A, Halvorsen B, Røttingen JA, Tacconelli E, Yazdanpanah Y, Olsen IC, Costagliola D; EU SolidAct study group. Trøseid M, et al. Crit Care. 2023 Jan 10;27(1):9. doi: 10.1186/s13054-022-04205-8. Crit Care. 2023. PMID: 36627655 Free PMC article. Clinical Trial.
Haemophagocytosis in bone marrow aspirates in patients with COVID-19.
Debliquis A, Harzallah I, Mootien JY, Poidevin A, Labro G, Mejri A, Lamarque M, Kuteifan K, Drénou B. Debliquis A, et al. Among authors: mootien jy. Br J Haematol. 2020 Jul;190(2):e70-e73. doi: 10.1111/bjh.16860. Epub 2020 Jun 12. Br J Haematol. 2020. PMID: 32529634 Free PMC article. No abstract available.
31 results